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Introduction
Sickle cell disease (SCD) is a genetic haematological 
disorder with its clinical manifestation starting usually in 
early childhood and sometimes during infancy. There are 
different forms of  SCD but individual homozygous for the 
HbS gene has the most severe form called sickle cell anemia 
(SCA)1,2.  It affects millions of  people around the world but 
the greatest burden of  SCD is in sub-Saharan Africa (SSA), 
where approximately 75% of  the global 300,000 births of  
affected children occur1,2.  Understandably,  because of  its 
large population, Nigeria has the largest burden of  SCD in 
Africa with a prevalence of  20-30 per 1000 live births and 
SCA is the variant of  SCD commonly encountered3. The 
Nigerian government responded to the huge disease burden 
recently by launching a national guideline for the care of  
person with SCD in November 20144. The disease condition 
is characterized by chronic hemolytic anaemia, severe painful 
episodes due to vaso-occlusion and multi-organ ischaemic 
damage which inadvertently affects the quality of  life of  
these patients5.  Also, patients with SCD are more prone 
to bacterial infections and severe forms of  malaria due to 
reduced splenic activity.  The World Health Organization 
(WHO) has identified that most of  the mortalities caused by 
SCD and its complications can be prevented through simple 
and cost-effective comprehensive care6. These include the 
immediate treatment of  acute events and prophylaxis against 
infections through vaccinations and other medications. 
The treatment of  the symptoms of  SCD includes adequate 
hydration, blood transfusion, use of  analgesics, antibiotics, 
and anti-malarial drugs. 
Despite the established fact that pain secondary to vaso-
occlusive crisis is the most common symptom of  SCD and 
responsible for presentation at the emergency department, 
studies conducted worldwide have shown a gross under-
treatment of  pain7,8. Also, the use of  prophylactic medications 
and vaccinations has been shown to be effective in preventing 
infections in patients with SCD9,10. These aspects of  care 
and others are well outlined in the newly launched guidelines 
for the care of  persons with SCD in Nigeria. For example, 
the guideline stipulates that children with SCD should 
have prophylaxis for malaria and bacterial infections with 
proguanil and penicillin V respectively. In addition, they are 
required to recieve some additional vaccines among other 
cares4.
A prescription audit represents a veritable tool for 
establishing the pattern of  disease treatment generally 
among patients11. In addition to establishing pattern of  drug 
use, audit of  prescriptions is essential to identify various 
categories of  non-rational drug prescribing such as poly-
pharmacy and irrational use of  antibiotics12.  Prescription 
audits also describe trends in management of  diseases and 
adherence to established international or national treatment 
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guidelines13. Non-rational prescription of  antibiotics is 
associated with antimicrobial resistance, treatment failures 
and increased healthcare costs14. In patients with SCD, a 
prescription audit would give information about types of  
analgesics, antibiotics and anti-malarial drugs prescribed 
for patients. Some prescription audits have previously been 
conducted among children attending the children outpatient 
clinics of  secondary and tertiary healthcare centres in 
Nigeria,15-17 but to the knowledge of  the authors this is the 
first study on drug prescribing pattern among paediatric 
SCD patients.  The main objective of  this study was to 
assess the pattern of  drug prescription in children with 
SCD attending a paediatric outpatients’ clinic of  a tertiary 
care centre in Ado-Ekiti, South-West Nigeria. Additional 
objectives included associated co-morbid conditions and 




The study was conducted in the paediatric outpatient clinic 
of  the Ekiti State University Teaching Hospital, Ado-Ekiti, 
South-West Nigeria. This tertiary level healthcare facility 
provides medical care for the population of  Ado-Ekiti, the 
capital city, and other communities in Ekiti State, South-West 
Nigeria. The paediatric department is well staffed with its 
components of  medical officers, registrars, consultants and 
nursing staff  and runs a weekly haematology clinic where 
patients with SCD are seen. The department also runs an 
emergency unit where patients that require observation 
and admission are attended to. There were 238 registered 
patients at the paediatric SCD clinic at the time of  this 
review out of  which only 208 attend the clinic regularly. 
The regular attendees comprised 136 (65.4%) males and 72 
(34.6%) females. All diagnoses of  disease conditions were 
made based on clinical features and laboratory confirmation. 
For example, all cases of  suspected malaria i.e. children 
presenting with fever (axillary temperature ≥ 37.5◦C) and no 
other clinical features referable to other illnesses apart from 
malaria, had parasitological tests to confirm the diagnosis of  
malaria through blood film examination by light microscopy 
and or rapid diagnostic test kits.
Method
A cross-sectional retrospective study was carried out using 
the medical records of  all patients with SCD who attended 
the paediatric outpatients’ clinic of  the teaching hospital 
between January 1 and December 31, 2014. The data was 
extracted from the case notes during the months of  January 
and February, 2015.
Sampling procedure
Using convenience sampling, medical records of  all children 
and adolescents (<18 years) with SCD who attended the 
SCD clinic during the one year period were selected for 
the study. Records of  patients who were admitted to the 
emergency room or the wards because of  the severe nature 
of  their presentation were excluded from the study.
Data collection
The information retrieved from the case notes included the 
bio-demographic data, associated co-morbid conditions and 
the list of  prescribed drugs. Also, the dosages and routes 
of  administration of  the medications were recorded. A data 
collection instrument was developed by the researchers 
based on the items listed above and pre-tested using medical 
records of  ten patients to identify potential problems. Two 
medical officers were trained by the principal investigator on 
how to record the required information and the completed 
data forms were reviewed by two of  the co-investigators to 
ensure that all vital information was correctly captured. The 
following drug use indicators were assessed using the WHO 
guidelines on investigation of  drug use in health care facilities: 
average number of  drugs per prescription, percentage 
of  encounters with antibiotics, percentage of  encounters 
with analgesics, percentage of  drugs prescribed by generic 
name and percentage of  encounters with injections18. The 
percentage of  encounters with anti-malarial drugs was also 
included as the study was conducted among children and 
adolescents residing in a malaria endemic area.
Statistical Analysis
Data were analyzed using Statistical Package for Social Sciences 
(SPSS) version 17 software (IBM Corporation, Armonk, 
NY, USA). Results were expressed as means, frequencies 
and percentages. Chi square was used to determine the level 
of  significance of  groups of  categorical variables with P 
values <0.05 considered significant. Association between 
age groups, number of  drugs per prescription, number of  
analgesic drugs and number of  antimicrobials was explored 
by univariate analysis.
Ethical Considerations
Ethical approval was obtained from the Hospital Research 
Ethics Committee before the commencement of  the study.
Results
The medical records of  202 SCD patients were used for the 
study. Males accounted for 61.9% while children less than 
5 years formed the largest group (87; 43.1%) followed by 
those between 5-10 years (81; 40.1%) and those above 10 
years (34; 16.8%). The mean age of  all patients was 6.9 ±3.8 
yrs. Malaria (80; 39.6%) and respiratory tract infection (32; 
15.8%) were the most common co-morbid conditions while 
vaso-occlusive crisis (40; 19.8%) was the most diagnosed 
sickling syndrome. Table 1 shows some of  the demographic 
details and established diagnoses (please note that patients 
may have one or more co-morbidities).
A total of  1015 medications were prescribed during the 
study period giving a mean of  5.02 ± 1.9. Figure 1 shows 
the frequency distribution of  prescribed medications. 
Seventy-eight patients (38.6%) had four medications or 
less prescribed while 124 (61.4%) had more than four 
medications. Vitamins/micronutrients, anti-malarial drugs, 
antibiotics and analgesics accounted for 41.4%, 29.0%, 
15.7% and 13.9% of  all prescribed drugs respectively. One 
hundred and ninety patients (94.1%) had at least one anti-
malarial drug prescribed while 183 (90.6%), 139 (68.8%) and 
124 (61.4%) had an encounter with vitamins, antibiotics and 
analgesics respectively. Thirty-six patients (17.8%) had drugs 
administered in injectable form.
A total of  159 antibiotics were prescribed with drugs from 
the penicillin group   most commonly prescribed followed 
by macrolides and cephalosporins (Figure 3). Erythromycin 
(38; 23.8%), Amoxycillin/Clavulanic acid (30; 18.8%), 
Cefuroxime (26; 16.3%), Amoxycillin (18; 11.3%) and 
Ciprofloxacin (12; 7.5%) were the most common prescribed 
antibiotics. Paludrine, the prophylactic anti-malarial, was 
prescribed for (92; 48.4%) patients while the artemisinin-
http://dx.doi.org/10.4314/mmj.v29i4.1
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morbidities. Antibiotic prescribing reported in some studies 
among non-SCD patients range between 28% and 33.3% 
and this is much higher than what is found in this study.17,31,32 
This may also be due to the approach of  clinicians towards 
management of  febrile illness in children with unjustified 
prescription of  antibiotics. Non-rational prescription and 
use of  antibiotics is associated with increased antimicrobial 
resistance, worsening morbidity and increased healthcare 
costs especially in resource-limited settings33-35. Prophylactic 
penicillin has been found to be effective in the prevention of  
pneumococcal infections among SCD patients especially in 
children less than five years old9,36. In this study, no patient 
had penicillin prophylaxis, a practice not in keeping with 
internationally accepted guidelines37. In a recent Nigerian 
study conducted across 18 sickle cell clinics, only eight 
of  them routinely gave prophylactic penicillin38. This is in 
contrast to a study conducted in Brazil where 76.1% of  the 
patient population received penicillin prophylaxis39.
The prophylactic anti-malarial Proguanil (Paludrine®) was 
prescribed for 92(48.4%) patients; this is much less than 
73.4% reported among SCD patients in North-west Nigeria25. 
The need for prompt and effective treatment of  malaria and 
infections in patients presenting in the clinic may explain 
this relatively low level of  Proguanil prescription during the 
acute phase of  illness.  The artemisinin-based combinations 
(Artesunate-Amodiaquine and Artemeter-Lumefantrine) 
were the most commonly used antimalarial drugs in keeping 
with findings from other Nigerian studies17,40.
Vaso-occlusive crisis manifesting as bone pains is a major 
cause of  emergency room visits and hospitalizations hence 
pain relief  is a core aspect of  treating patients with SCD. 
Analgesics  constituted 13.9% of  all prescribed drugs with 
124 (61.4%) having at least one analgesic drug; a finding that 
is lower than 30.1% recorded in the earlier cited study among 
sickle cell patients in North-west Nigeria25.  Ibuprofen and 
Acetaminophen were the most prescribed analgesics in this 
study while only one patient had Pentazocine (an opioid) 
prescribed. This might be due to the perceived degree of  
the pain severity by the attending physicians, given the belief  
that most patients with severe pains will be taken directly to 
the children emergency ward in the hospital. Also, studies 
have shown a tendency towards under-prescribing of  opioid 
analgesics by medical practitioners because of  perceived 
fear of  both physical and psychological dependence41,42. For 
these reasons, the attending physicians may have avoided 
prescribing opioid analgesics for outpatients even though 
there is no regulation against the practice. This finding 
is in keeping with the results of  a systematic  review of  
paediatric analgesic use in Africa which reported that only 
0.2% of  children had opioid analgesic prescribed43. This 
is in contrast to current guidelines that recommend rapid 
initiation of  opioids in the management of  vaso-occlusive 
crises37. Inadequate treatment of  pain among patients with 
SCD is one of  the shortfalls of  the management of  SCD 
and it has been attributed to the wrong perception of  
caregivers and physicians about psychological dependence 
or addiction following opioid use8,44. Also, the subjectivity 
of  the reported pain and the coping ability of  patients may 
affect the way pain is observed by patients’ relatives and 
medical staff7,45. Strategies that have been used to address the 
poor management of  pain among patients with SCD include 
the use of  various pain assessment scales and addressing 
the psychosocial component of  the experience46-48. Findings 
from other studies linked inadequate analgesia in patients 
based combination of  Artesunate-Amodiaquine (40; 21.1%) 
and Artemether-Lumefantrine (37; 19.5%) were prescribed 
for the treatment of  acute malaria. Ibuprofen (85; 60.3%), 
Acetaminophen (46; 32.6%) and Diclofenac (9; 6.4%) 
were the commonly prescribed analgesics. Pentazocine was 
prescribed only for one patient among the study participants.
A comparison of  the mean total number of  prescribed 
drugs and antibiotics among the three age groups was not 
statistically significant (P= .308 and .650 respectively). There 
was however a statistically significant difference in the mean 
number of  prescribed analgesics between the three age 
groups (P = .004).
Discussion
This study has described the morbidity pattern and the drugs 
prescribed in the treatment of  children with Sickle cell disease 
in a centre in South-west Nigeria. Children aged less than five 
years formed the bulk of  study participants; this is not too 
surprising as the diagnosis of  SCD is made usually during 
this period and caregivers are faced with the challenges of  
how to manage this condition. Also, during these early years, 
the immunity of  the children is not well developed to be able 
to withstand the assault of  the myriads of  infections they are 
susceptible to. In fact, mortality in children with SCD has 
been documented to be highest among the under-five age 
group19, 20. 
Malaria and respiratory tract infections were the most 
common medical conditions in children with SCD presenting 
at the healthcare facility. This is not surprising as the study 
area is located within the holo-endemic malaria transmission 
region. It is also an established fact that infections and 
malaria are among the most common triggers of  different 
types of  crisis necessitating admissions in children with 
SCD.21, 22Vaso-occlusive crisis was the most frequently 
diagnosed clinical phenotype among patients in this study, 
similar to results from work carried out by Ibidapo et al and 
Olabode et al in Lagos and Ibadan, Nigeria respectively23,24. 
This finding buttresses the earlier mentioned role of  malaria 
and infections as triggers of  crisis in SCD21,22.
The mean number of  prescribed drugs found in this study 
was 5.0 ± 1.9,  similar to 4.5 reported by Jimoh et al in a 
study conducted among patients with SCD in North-west 
Nigeria25. For the under-fives in this study, the mean of  
prescribed drugs was 4.9 much higher than 2.6 and 3.1 
reported in other Nigerian studies conducted among children 
younger than five years of  age17,26. Similar findings have also 
been reported in studies conducted among children in India, 
Oman and Italy with a mean number of  prescribed drugs 
2.3, 2.3 and 3.1 respectively27-29. The higher mean reported in 
studies conducted among patients with SCD is likely due to 
differences in patient population, associated co-morbidities 
and routine medications prescribed for them. These routine 
medications are however very necessary  because patients 
with SCD  are more prone  to certain infections due to their 
poorer immunity status30.
A total of  159 antibiotics were prescribed for patients in 
this study, representing 15.7% of  all prescribed medications 
in this study with 68.8% of  patients having at least one 
antibiotic prescribed. This result is higher than 8.7% reported 
in the earlier cited study among SCD patients in Nigeria25. 
This difference may be due to the fact that the latter study 
included both paediatric and adult patients with SCD with 
different profiles of  clinical sickling syndromes and co-
http://dx.doi.org/10.4314/mmj.v29i4.1
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with SCD with worsening morbidity and adverse effects on 
the overall quality of  life hence, the need for interventions to 
improve on this practice5,8.
The use of  hydroxyurea has contributed significantly to the 
reduction in morbidity and mortality and improvement of  
quality of  life of  patients with SCD37,49. None of  the patients 
was on hydroxyurea during the duration of  this study and 
this may be due to poor knowledge and perception of  
physicians towards its use and the issue of  cost and its side 
effects. A recent comparative study among sickle cell patients 
from Nigeria and the USA showed significant lower use of  
hydroxyurea among the Nigerian cohort50. Also the locally 
developed anti-sickling agent, Ciklavit®,  which has been 
found to be effective in reducing sickling episodes, was not 
prescribed for any of  the patients during the study51. This 
brings to fore the need for government to either subsidize 
these medications to ensure their affordability or speed up 
its coverage under the National Health Insurance Scheme.
Study Limitations
This study was conducted in only one centre and this fact 
may affect the generalization of  its results. We are also aware 
of  the possibility of  patients using drugs not prescribed 
by doctors especially as the regulatory environment for 
medicines in Nigeria is poor; hence the possibility of  under-
reporting of  drug use among this population. Though 
majority of  the patients were booked for routine clinic 
appointment, some might have presented acutely with 
resultant effects on the drug prescription pattern. It was 
also noted that very few prescription audits among patients 
with SCD had been conducted in Nigeria and indeed the 
sub-Saharan region hence the inability of  finding similar 
studies for comparison of  results. This might impact on the 
interpretation of  our results in the context of  the general 
population. Finally, the retrospective nature of  the study may 
be associated with missing data and other vital information 
that may be relevant. This was observed in this study as 
records of  six patients could not be traced for analysis.
Conclusion
High rate of  antibiotic prescription, low use of  opioid 
analgesics and non- prescription of  prophylactic penicillin/ 
pneumococcal vaccination were the main findings in this 
study. There is a need to update medical practitioners on 
the comprehensive approach to the management of  SCD 
through introduction of  treatment protocols. Inadequate 
analgesia in patients with SCD, apart from worsening 
morbidity, will also affect the overall quality of  life. The 
observed gapsin the care of  patients with SCD raise the need 
for health care providers to adhere to established guidelines 
and protocols while managing their patients. In view of  the 
above, all efforts should be made to improve on every aspect 
of  care and management of  SCD patients by domesticating 
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